Overview

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Status:
Completed
Trial end date:
2017-11-07
Target enrollment:
Participant gender:
Summary
Access the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy Japanese participants after multiple doses are administered.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb